The story has been updated to include comments from Danaher's conference call this morning.

NEW YORK (GenomeWeb News) – Danaher's sales for the third quarter rose 6 percent year over year as its Life Sciences and Diagnostics segment grew almost 11 percent, the company reported today.

For the three months ended Sept. 27, the Washington-based conglomerate saw sales improve to $4.67 billion from $4.42 billion a year ago, edging out the consensus Wall Street estimate of $4.62 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.